By targeting unique biological mechanisms and/or employing novel formulations, Redwood Pharma’s dry eye therapies RP101 and RP501 offer new therapeutic solutions to patients.
As the causes of dry eye disease are varied, Redwood Pharma’s therapeutic solutions can address large unmet medical needs in a broad spectrum of applications, as well as in the largest patient population.
Redwood Pharma takes important steps towards the commercial production of its dry eye product
Redwood Pharma enters partnership with Nextec medical in preparation for European market clearance of RP501
Redwood Pharma to present at AKTIEPORTFÖLJEN LIVE SVERIGE in Stockholm on 11th of Oct. 2022 at 14:45
Redwood Pharma at Aktieportföljen Live